GlaxoSmithKline Pharmaceuticals Limited — Updates, 13-05-2026: Press Release

GSK India reported strong Q4 and full-year results, with full-year revenue at 3790 Cr (+2%) and PAT at 1012 Cr (+10%). EBITDA margins expanded to 34%. Board proposed a final dividend of Rs. 57/share. Oncology portfolio and Vaccines showed momentum, plus market authorization for Blenrep.